| Species |
Human |
| Protein Construction |
| Avi |
His |
IL-5 (Ile20-Ser134)
Accession # P05113 |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human IL5 R alpha, hFc Tag at 2μg/ml (100μl/Well) on the plate can bind IL-5[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
16.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 18-25 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA). |
| Synonyms |
Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
